# Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

> **NCT03805932** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Hairy Cell Leukemia

## Interventions

- **DRUG:** Moxetumomab Pasudotox-tdfk
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Ruxience
- **DRUG:** Dexamethasone
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine
- **DRUG:** Famotidine
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT03805932
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-03
- **Primary completion:** 2023-07-07
- **Final completion:** 2026-06-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03805932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03805932, "Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03805932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*